Two Sigma Investments LP Takes Position in Fate Therapeutics (FATE)

Two Sigma Investments LP bought a new stake in Fate Therapeutics (NASDAQ:FATE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 170,636 shares of the biopharmaceutical company’s stock, valued at approximately $1,043,000. Two Sigma Investments LP owned about 0.33% of Fate Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of FATE. The Manufacturers Life Insurance Company raised its stake in shares of Fate Therapeutics by 61.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 12,686 shares during the last quarter. California State Teachers Retirement System bought a new position in shares of Fate Therapeutics in the second quarter valued at approximately $219,000. Russell Investments Group Ltd. bought a new position in shares of Fate Therapeutics in the third quarter valued at approximately $234,000. Two Sigma Advisers LP raised its stake in shares of Fate Therapeutics by 257.0% in the fourth quarter. Two Sigma Advisers LP now owns 71,400 shares of the biopharmaceutical company’s stock valued at $436,000 after acquiring an additional 51,400 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Fate Therapeutics by 167.6% in the third quarter. Neuberger Berman Group LLC now owns 133,000 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 83,300 shares during the last quarter. Institutional investors own 66.41% of the company’s stock.

How to Become a New Pot Stock Millionaire

FATE stock opened at $9.28 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 9.29 and a current ratio of 9.29. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $14.45.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue was up .0% on a year-over-year basis. sell-side analysts predict that Fate Therapeutics will post -0.94 EPS for the current year.

A number of research firms have recently issued reports on FATE. Wedbush reiterated an “outperform” rating and issued a $19.00 target price on shares of Fate Therapeutics in a research note on Thursday, March 29th. ValuEngine upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. HC Wainwright cut shares of Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a research report on Tuesday, March 6th. UBS cut shares of Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. Finally, Zacks Investment Research cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.00.

WARNING: “Two Sigma Investments LP Takes Position in Fate Therapeutics (FATE)” was first published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3340815/two-sigma-investments-lp-takes-position-in-fate-therapeutics-fate.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

COPYTRACK Price Tops $0.21 on Major Exchanges
COPYTRACK Price Tops $0.21 on Major Exchanges
Quantstamp  Price Up 30% This Week
Quantstamp Price Up 30% This Week
Carvana  versus Its Peers Head-To-Head Comparison
Carvana versus Its Peers Head-To-Head Comparison
Comparing Gold Fields  & The Competition
Comparing Gold Fields & The Competition
Contrasting Saratoga Resources  and Petroleum Geo-Services
Contrasting Saratoga Resources and Petroleum Geo-Services
U.S. Geothermal  Receives Average Recommendation of “Hold” from Brokerages
U.S. Geothermal Receives Average Recommendation of “Hold” from Brokerages


© 2006-2018 Ticker Report. Google+.